Research Pipeline

Candidate & Indication Research Stage
Discovery Preclinical
SYN-005 Pertussis (Whooping Cough)
Discovery Phase complete
Preclinical Phase in progress
SYN-200 Phenylketonuria (PKU)
Discovery Phase in progress
Preclinical Phase not started

Collaborative Partners

SYN-005

Through our August 2012 Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE: XON) and academic researchers at The University of Texas at Austin (UT Austin), we are developing SYN-005, a combination of two humanized antibodies that includes hu1B7, for the treatment of critically ill infants with Pertussis. In addition, UT Austin was awarded a grant from the Gates Foundation to generate preclinical proof-of-concept data to test the hypothesis that hu1B7 antibody administration at birth may also have a role in the prevention of Pertussis. Jennifer Maynard, Ph.D., the principal investigator of the grant at UT Austin, will test this hypothesis by using our hu1B7 antibody.

SYN-200

Through our August 2015 ECC with Intrexon Corporation, we are pursuing the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder. Through the ECC, we plan to utilize Intrexon's ActoBiotics™ platform which is a proprietary method of delivering therapeutic protein and peptides to the gastrointestinal (GI) tract through food-grade microbes.